PTO/SB/68 (07-03)
Approved for use through 7/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

*Bring completed form to:*
File Information Unit
Crystal Plaza Three, Room 1D01
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733




In re Application of

| Application Number | Filed |
|---|---|
| 07/310,252 | 2-13-89 |

Paper No. 54

**I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):**

United States Patent Application Publication No. _____, page, _____ line _____,

United States Patent Number 5,585,089, column _____, line, _____ or

WIPO Pub. No._____, page _____, line _____.

## Related Information about Access to Pending Applications (37 CFR 1.14):

**Direct access to pending applications is not** available to the public but **copies** may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:
the file contents;
the pending application as originally filed; or
any document in the file of the pending application.

For unpublished applications that are still pending:

(1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
the file contents;
the pending application as originally filed; or
any document in the file of the pending application.

(2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
the pending application as originally filed.

Rachel Hall
Signature

06-07-04
Date

Rahel Haile
Typed or printed name

Registration Number, if applicable

703-486-1150
Telephone Number

FOR PTO USE ONLY

Approved by: _____ (initials)

Unit: _____

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.

US005585089A

# United States Patent [19]

Queen et al.

[11] Patent Number: 5,585,089

[45] Date of Patent: Dec. 17, 1996

[54] **HUMANIZED IMMUNOGLOBULINS**

[75] Inventors: **Cary L. Queen**, Los Altos; **Harold E. Selick**, Belmont, both of Calif.

[73] Assignee: **Protein Design Labs, Inc.**, Mountain View, Calif.

[21] Appl. No.: **477,728**

[22] Filed: **Jun. 7, 1995**

**Related U.S. Application Data**

[63] Continuation of Ser. No. 634,278, Dec. 19, 1990, Pat. No. 5,530,101, which is a continuation-in-part of Ser. No. 590, 274, Sep. 28, 1990, abandoned, and Ser. No. 310,252, Feb. 13, 1989, abandoned, which is a continuation-in-part of Ser. No. 290,975, Dec. 28, 1988, abandoned.

[51] **Int. Cl.**[6] ..... **C07K 16/18**; A61K 39/395

[52] **U.S. Cl.** ..... **424/133.1**; 530/387.3; 530/388.22; 424/143.1

[58] **Field of Search** ..... 530/387.3, 388.22; 424/133.1, 143.1

[56] **References Cited**

U.S. PATENT DOCUMENTS

| | | | |
|---|---|---|---|
| 4,578,335 | 3/1986 | Urdal et al. | 530/351 |
| 4,816,397 | 3/1989 | Boss et al. | 435/68 |
| 4,816,565 | 3/1989 | Honjo et al. | 435/69.1 |
| 4,816,567 | 3/1989 | Cabilly et al. | 530/387 |
| 4,845,198 | 7/1989 | Urdal et al. | 530/387.3 |
| 4,867,973 | 9/1989 | Goers et al. . | |
| 5,198,359 | 3/1993 | Taniguchi et al. | 435/252.3 |
| 5,225,539 | 7/1993 | Winter | 530/387.3 |

FOREIGN PATENT DOCUMENTS

| | | | |
|---|---|---|---|
| 0171496 | 2/1986 | European Pat. Off. | C12N 15/00 |
| 0173494 | 3/1986 | European Pat. Off. | C12N 15/00 |
| 0184187 | 6/1986 | European Pat. Off. | C12N 15/00 |
| 0256654 | 7/1987 | European Pat. Off. . | |
| 0239400 | 9/1987 | European Pat. Off. . | |
| 0266663 | 6/1988 | European Pat. Off. | C12N 15/00 |
| 2188941 | 10/1987 | United Kingdom | C12N 5/00 |
| 86/05513 | 9/1986 | WIPO | C12N 15/00 |
| 87/02671 | 5/1987 | WIPO | C07H 15/12 |
| 89/01783 | 3/1989 | WIPO | A61K 39/395 |

OTHER PUBLICATIONS

Riechmann et al. Nature vol. 332 24, Mar. 1988 p. 323.

Foote, Nova Acta Leopoldina 1989. vol. 61 (269) 103.

Amit et al. Science vol. 233 1986 p. 747.

Groves et al. vol. 6, 1987, p. 71.

Better et al., "*Escherichia coli* Secretion of an Active Chimeric Antibody Fragment", *Science* 240:1041–1043 (1988).

Bird et al., "Single–Chain Antigen–Binding Proteins", *Science* 242:423–426 (1988).

Boulianne et al., "Production of functional chimeric mouse/human antibody," *Nature* 312:643–646 (1984).

Carter et al., "Humanization of an anti–p185$^{HER2}$ antibody for human cancer therapy," *Proc. Natl. Acad. Sci.* 89:4285–4289 (1992).

Chothia, C. and A. M. Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins", *J. Mol. Biol.* 196:901–917 (1987).

Co et al., "Humanized antibodies for antiviral therapy," *Proc. Natl. Acad. Sci. USA* 88:2869–2873 (1991).

Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," *J. of Immunol.* 148(4):1149–1154 (1992).

Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR–grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nuc. Acids Res.* 19:2471–2476 (1991).

Ellison et al., "The nucleotide sequence of a human immunoglobulin C(gamma)$_1$gene", *Nucleic Acids Res.* 10:4071–(1982).

Farrar, J., "The biochemistry, biology, and role of interleukin–2 in the induction of cytotoxic T cell and antibody-forming B cell receptors," *Immunol. Rev.* 63:129–166 (1982).

Foote et al., "Antibody framework residues affecting the conformation of hypervariable loops," *J. Mol. Biol.* 224:487–499 (1992).

Gorman et al., "Reshaping a therapeutic CD4 antibody," *Proc. Natl. Acad. Sci.* 88:4181–4185 (1991).

Greene et al., "Growth of Human T Lymphocytes: An Analysis of Interleukin 2 and Its Cellular receptor", in *Progress in Hematology XIV*, E. Brown, ed., Grune and Statton, New York (1986) pp. 283–301.

Hale et al., "Remission Induction in Non–Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody CAMPATH–1H", *Lancet* Dec. 17, 1988, pp. 1394–1399.

Hieter et al., "Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments", *Cell* 22:197–207 (1980).

(List continued on next page.)

*Primary Examiner*—Lila Feisee

*Attorney, Agent, or Firm*—Townsend and Townsend and Crew LLP

[57] **ABSTRACT**

Novel methods for producing, and compositions of humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

**11 Claims, 55 Drawing Sheets**

OTHER PUBLICATIONS

Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti–digoxin single–chain Fv analogue produced in *Escherichia coli*", *Proc. Natl. Acad. Sci. U.S.A.* 85:5879–5883 (1988). in *Progress in Hematology XIV*, E. Brown, ed., Grune and Statton, New York (1986) p. 283.

Jones et al., "Replacing the complementarity–determining regions in a human antibody with those from a mouse", *Nature* 321:522–525 (1986).

Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR–grafting: the importance of framework residues on loop conformation," *Protein Engineering* 4:773–783 (1991).

Kirkman et al., *Journal of Expt. Med.* vol. 162:358 Jul. 1985.

Leonard et al., "The human receptor for T–cell growth factor," *J. Biol. Chem.* 260:1872–1880 (1985).

Liu et al., "Expression of mouse::human immunoglobulin heavy–chain cDNA in lymphoid cells", *Gene* 54:33–40 (1987).

Maeda et al., "Construction of reshaped human antibodies with HIV–neutralizing activity", *Hum. Antibod. Hybrid.* 2:124–134 (1991).

Morrison et al., "Chimeric human antibody molecules: Mouse antigen–binding domains with human constant region domains," *Proc. Natl. Acad. Sci.* 81:6851–6859 (1984).

Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies," *Science* 229:1202–1207 (1985).

Neuberger et al., "A hapten–specific chimeric IgE antibody with human physiological effector function," *Nature* 314:268–270 (1985).

Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," *Proc. Natl. Acad. Sci. USA* 86:10029–10033 (1989).

Riechmann et al., "Reshaping human antibodies for therapy", *Nature* 332:323–327 (1988).

Routledge et al., "A humanized monovalent CD3 antibody which can activate homologous complement," *Eur. J. Immunol.* 21: 2717–2725 (1991).

Sahagan et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor–Associated Antigen", *J. Immunol.* 137:1066–1074 (1986).

Shalaby et al., "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene," *J. Exp. Med.* 175:217–225 (1992).

Sharon et al., "Expression of a $V_HC_K$ chimaeric protein in mouse myeloma cells", *Nature* 309:364–367 (1984).

Shearman et al., "Construction, expression and characterization of humanized antibodies directed against the human α/β T cell receptor," *J. Immunol.* 147(12):4366–4373 (1991).

Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", *Nature* 314:452–454 (1985).

Tan et al., "A Human–Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells", *J. Immunol.* 135:3564–3567 (1985).

Tempest et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo," *Bio/Technology* 9:226–271 (1991).

Uchiyama et al., "A monoclonal antibody (anti–Tac) reactive with activated and functionally mature human T–cells," *J. Immunol.* 126:1393–1397 (1981).

Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", *Science* 239:1534–1536 (1988).

Vitteta et al., "Redesigning Nature's Poisons to Create Anti–Tumor Reagents," Science 238:1098–1104 (1987).

Waldmann, T. A., "The Structure, Function, and Expression of Interleukin–2 Receptors on Normal and Malignant Lymphocytes," *Science* 232:727–732 (1986).

Woodle et al., "Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression," *J. Immunol.* 148:2756–2763 (1992).

Junghans et al., *Cancer Res.*, 50:1495–1502 (1990).

Kupiec–Weglinski et al., *Proc. Natl. Acad. Sci.*, 83:2624 (1986).